➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Dow
McKinsey
Harvard Business School
Moodys

Last Updated: July 23, 2021

DrugPatentWatch Database Preview

EPI E Z PEN JR Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Epi E Z Pen Jr patents expire, and what generic alternatives are available?

Epi E Z Pen Jr is a drug marketed by Mylan Speciality Lp and is included in one NDA.

The generic ingredient in EPI E Z PEN JR is epinephrine. There are twenty-one drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Epi E Z Pen Jr

A generic version of EPI E Z PEN JR was approved as epinephrine by BELCHER on July 29th, 2014.

  Try it Free

Paragraph IV (Patent) Challenges for EPI E Z PEN JR
Tradename Dosage Ingredient NDA Submissiondate
EPIPEN JR. INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS epinephrine 019430 2009-07-20
EPI E Z PEN JR INJECTABLE;INTRAMUSCULAR epinephrine 019430 2009-07-20
EPIPEN E Z PEN INJECTABLE;INTRAMUSCULAR epinephrine 019430 2009-07-20
EPIPEN INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS epinephrine 019430 2009-07-20

US Patents and Regulatory Information for EPI E Z PEN JR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp EPI E Z PEN JR epinephrine INJECTABLE;INTRAMUSCULAR 019430-004 Aug 3, 1995 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Dow
McKinsey
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.